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In idiopathic pulmonary arterial hypertension, HA accumulation has been associated with advanced disease. In this study, we investigated the potential role of HA degradation in the early stages of disease by examining HA distribution, molecular mass, synthesis, and enzymatic degradation at different stages of disease progression in a rat model of monocrotaline (MCT)-induced pulmonary hypertension (PH). At 28 days post-MCT, severe PH was associated with increased total lung HA (P ϭ 0.04). In contrast, a significant decrease in total lung HA was observed on day 10, before the onset of PH (P ϭ 0.02). Molecular mass analysis revealed a loss of high molecular mass (HMM) HA at 10 and 24 days post-MCT, followed by an increase in HMM HA at 28 days. Expression of HA synthase 2 (HAS2) was elevated in MCT-challenged animals at 24 and 28 days, consistent with increased synthesis of HMM HA. Analysis by Morgan Elson assay and zymography demonstrated increased hyaluronidase-1 activity in the lungs of MCTchallenged rats, indicating that the observed increases in HAS2 expression and HA synthesis were counterbalanced, in part, by enhanced degradation. The present data demonstrate that, in the MCT model, early-stage PH is associated with enhanced hyaluronidase-1 activity, while both degradation and synthesis are increased at later stages. Thus an early increase in the generation of proinflammatory HA fragments may play a role in the onset and progression of pulmonary arterial hypertension.
hyaluronidase; hyaluronan synthase; lung; inflammation PULMONARY ARTERIAL HYPERTENSION (PAH) is characterized by extensive vascular remodeling, leading to increased pulmonary vascular resistance and eventual death by right heart failure. While most investigations into the pathogenesis of PAH focus on abnormalities of vascular endothelial and smooth muscle cells (SMCs), a number of reports have shown that degradation of the extracellular matrix may also contribute to this pathological vascular remodeling. Work by Rabinovitch and colleagues demonstrated elevated serine elastase activity in both clinical PAH (35) and animal models of disease (26, 44, 52) . Later studies also recognized a potential role for matrix metalloproteinases and their tissue inhibitors in the pathogenesis of PAH (6, 24, 47) . The suggestion from these studies was that enzymatic matrix degradation resulted in the release of matrixbound growth factors, which enhanced the survival and proliferation of vascular SMCs.
Recently, a number of studies have highlighted the capacity of matrix degradation fragments, such as low-molecular-mass (LMM) forms of the glycosaminoglycan (GAG) hyaluronan (HA), to directly stimulate innate inflammation and pathological vascular remodeling (7, 42) . HA is a linear, anionic polysaccharide composed of repeating units of the disaccharide [-D-glucuronic acid-␤1,3-N-acetyl-D-glucosamine-␤1,4-] n . Despite its simple structure, HA has been shown to possess a wide range of biological activities, which vary with molecular mass. High molecular mass (HMM) HA (20,000 -500 kDa) is immunosuppressive (9, 28) and anti-angiogenic (13) . Conversely, LMM HA fragments (Ͻ500 kDa) have been shown to act as an endogenous "danger signal," alerting the body to areas of localized injury and stimulating inflammation through macrophage (21, 37) , dendritic cell (43) , and endothelial cell (41)-mediated toll-like receptor signaling. LMM HA fragments have also been shown to act as a mitogenic and migratory stimulus for endothelial cells (50) and vascular SMCs (7). While these inflammatory and angiogenic functions are essential for tissue repair, chronic accumulation of HA fragments has been linked to several pathologies, including chronic obstructive pulmonary disease (10), atherosclerosis (7) , and autoimmune diseases, such as rheumatoid arthritis (30) .
In the context of idiopathic PAH (IPAH), matrix degradation and the resultant accumulation of proinflammatory HA fragments could be responsible for initiating the chronic inflammation that has been linked to pathological vascular remodeling (8, 40, 46) . The mitogenic capacity of HA fragments may also contribute to the aberrant proliferation of endothelial cells and vascular SMCs that lead to vascular occlusion and increased pulmonary vascular resistance. Recently, two studies reported increased levels of HA in the lungs and plasma of patients with IPAH (2, 33) . While these studies effectively demonstrated an accumulation of HA in association with IPAH, neither study found an increase in LMM HA or the enhanced hyaluronidase activity that could lead to the generation of HA fragments (2, 33) . This may be due to the fact that the human samples in these reports were obtained from patients with advanced, end-stage disease, whereas enhanced HA degradation may be more prominent at earlier stages of disease progression.
We hypothesized that the early stages of PAH are associated with the enhanced enzymatic degradation of lung HA and the generation of bioactive LMM HA fragments. Using the monocrotaline (MCT) rat model of PAH, we investigated the accumulation, distribution, molecular mass, synthesis, and enzymatic degradation of HA in the lungs of MCT-challenged rats, both before the onset of elevated pulmonary arterial pressure, and at later stages of disease progression. We found enhanced hyaluronidase activity in the lung both before the onset of MCT-induced pulmonary hypertension (PH) and during the progression toward late-stage disease. In agreement with previous clinical studies, we also demonstrated a significant increase in total lung HA in association with late-stage disease in the MCT model. However, early stages of disease were associated with a decrease in total lung HA, due mainly to the loss of HMM HA isoforms. Thus, during disease progression, there is a shift in the balance between degradation and synthesis, with elevated hyaluronidase activity dominating at early stages, whereas enhanced synthesis of HMM HA is found in association with advanced disease.
MATERIALS AND METHODS
Protocol approval. All animal studies were conducted under ethics board-approved protocols in accordance with the guidelines of the Canadian Council on Animal Care.
MCT model of PH. Male Fisher 344 rats (Charles River, Wilmington, MA), weighing ϳ170 -200 g, were given intraperitoneal injections of MCT (70 mg/kg, Sigma, St. Louis, MO) or an equivalent volume of sterile water as a control. Animals were killed at 10 (n ϭ 8 -9 per group), 24 (n ϭ 5 per group), or 28 days (n ϭ 5 per group) after initiation of disease. Right ventricular (RV) systolic pressure (RVSP) was assessed immediately before death by cannulation of the right external jugular vein using a 3F ultra-miniature Mikro-Tip pressure transducer catheter (Millar, Houston, TX). RV hypertrophy was determined as a ratio of RV weight to left ventricular and septal weight (RV/LVϩS). Upon death, the lobes of the right lung were harvested and snap-frozen in liquid nitrogen for assessment of protein, HA, and mRNA. Left lungs were inflated and fixed in 4% phosphatebuffered paraformaldehyde, pH 7.2, before dehydration and embedding in paraffin.
Histology. Following dewaxing and rehydration, 6-m sections of lung tissue were treated with 3% H 2O2 for 10 min to remove endogenous peroxidase activity and incubated for 2 h at 37°C with 20 ng/ml of biotinylated HA binding protein (Calbiochem, San Diego, CA) in PBS with 0.25% BSA. Samples were then incubated for 30 min at room temperature with strept ABC complex/horseradish peroxidase (Dako, Glostrup, Denmark) and developed for 9 min with EnzMet (Nanoprobes, Yaphank, NY), producing a black precipitate. The sections were briefly counterstained with hematoxylin and washed under running tap water before dehydration and mounting with Cytoseal XYL (Thermo Fisher Scientific, Waltham, MA). Control samples were treated with bovine testicular hyaluronidase (Sigma) before labeling.
Ruthenium red staining for electron microscopy. Ruthenium red staining of GAGs in rat lung tissue was performed as described by Luft (25) . Ruthenium red stock solution was prepared by dissolving ruthenium red (Sigma) in distilled, deionized water at a concentration of 10 mg/ml, followed by heating for 30 min at 60°C with repeated agitation. The solution was centrifuged to remove undissolved particles, and the supernatant was collected and diluted to a concentration of 1,500 ppm (equivalent to 6.9 mg/ml) with distilled, deionized water. Immediately before death, a gluteraldehyde fixation buffer was prepared by mixing equal parts of 4% gluteraldehyde, 0.2M cacodylate buffer (pH 7.3), and 1,500 ppm ruthenium red stock solution. Rats were killed at 24 days following intraperitoneal injection of MCT or sterile water. Immediately following death, the pulmonary vasculature was perfused with the gluteraldehyde fixation buffer, followed by inflation of the lungs with fixation buffer by intratracheal injection. Tissues from random sections throughout the lungs were sectioned into 1-mm 3 segments and fixed at room temperature for 1 h. Following gluteraldehyde fixation, tissues were rinsed in 0.2 M cacodylate buffer three times over a 10-min period and fixed for 1.5 h in a mixture consisting of equal parts 2% OsO 4 in distilled water, 0.2 M cacodylate buffer, and 1,500 ppm ruthenium red stock solution. Following OsO 4 fixation, tissues were rinsed in 0.2 M cacodylate buffer three times over a 10-min period, dehydrated through an acetone series, and embedded in epoxy resin.
HA isolation and quantification. For each animal, a segment of snap-frozen right lung was pulverized under liquid nitrogen and subsequently lyophilized to obtain a dry weight. To remove HAassociated proteins that could interfere with quantification and molecular mass measurements, the samples were digested for 8 h in a pronase (Calbiochem) digestion buffer (50 mM Tris, pH 7.4, 0.15 M NaCl, 0.01 M CaCl, 5 mM deferoxamine mesylate, 20 U/ml pronase) at a concentration of 30 mg dry lung/ml. As described previously by Armstrong and Bell (1), deferoxamine mesylate (Sigma) was added to the buffer to inhibit iron-associated depolymerization of HMM HA. Following digestion, samples were boiled for 8 min to inactivate the pronase, centrifuged for 30 min at 21,000 g and 4°C, and passed through a 0.45-m Ultrafree-MC centrifugal filter unit (Millipore, Billercia, MA) to remove residual particulate matter. Quantification of total lung HA was assessed by ELISA (Echelon, Salt Lake City, UT), as per the manufacturer's instructions.
HA molecular mass by agarose electrophoresis. For the assessment of HA molecular mass, GAG isolates were additionally purified by precipitating out degraded protein with 7% trichloroacetic acid (Sigma) for 2 h at 4°C. Following precipitation, the suspension was centrifuged for 15 min at 21,000 g and 4°C. The supernatant was then dialyzed extensively against distilled, deionized water at 4°C using a Slide-a-lyzer dialysis cassette (10,000 MWCO, Thermo Fisher Scientific). Dialyzed samples were concentrated ϳ14-fold in a Vacufuge (Eppendorf, Hamburg, Germany) to a final volume of 14 l for analysis of GAG molecular mass by 0.5% Tris-acetate-EDTA (TAE)-agarose gel electrophoresis, as described by Lee and Cowman (23) . Purified GAG isolates were mixed with 2 l of 2 M sucrose loading buffer (2 M sucrose in 1ϫ TAE) and run at 47 V for 1 h and 45 min. Molecular mass standards (Hi-Ladder, 1,510 -495 kDa, and LoLadder, 495-25 kDa, Hyalose, Oklahoma City, OK) were run alongside samples to determine the molecular mass distribution of isolated GAGs. Immediately following electrophoresis, gels were stained with 0.005% stains-all (Sigma) in 50% ethanol for 24 h at room temperature in the dark. Gels were destained in distilled, deionized water for 48 h at room temperature in the dark, followed by a 1-h exposure to light to preferentially fade unbound dye. Nonsulfated HA appeared blue following destain and could be differentiated from other, sulfated GAGs, which appeared purple in color.
To gain a measure of LMM HA content in the lung isolates, additional gels were run using the technique described above. Following electrophoresis, the segment of each lane corresponding to the LMM HA range (Ͼ500 kDa) was cut out of the gel and placed in dialysis tubing (3,000-Da molecular mass cutoff, Thermo Fisher Scientific), and GAGs were recovered from the gel by electroelution, as described by Chouikh and colleagues (5). The electroeluted GAGs were then dialyzed in distilled, deionized water for 24 h. HA content of the samples was quantified by ELISA, as described above.
Real-time RT-PCR for HAS genes. For RNA isolation, segments of snap-frozen right lung tissue were homogenized in Trizol and purified by chloroform extraction, isopropanol precipitation, and subsequent washes with 75% ethanol. Purified RNA was dissolved in RNase/ DNase-free water (Invitrogen, Carlsbad, CA) and quantified by optical density using a ND-1000 spectrophotometer (Thermo Fisher Scientific). Reverse transcriptase reactions were performed using the Moloney murine leukemia virus enzyme (Invitrogen), as per manufacturer's instructions. Expression levels of HA synthase (HAS1, HAS2, and HAS3) and hyaluronidase 1 and 2 (HYAL1 and HYAL2) genes in MCT-treated and control animals were determined relative to the expression of ribosomal protein L32 (RPL32). Primers for realtime RT-PCR are shown in Table 1 .
Isolation and quantification of protein from rat lungs. Protein lysates were prepared from segments of snap-frozen right lung by pulverizing frozen tissues under liquid nitrogen. Pulverized samples were digested on ice for 20 -30 min in lysis buffer (50 mM Tris ⅐ HCl, pH 7.4, 1% Nonidet P-40, 150 mM NaCl, 0.25% sodium deoxycholate, 1 mM NaF, 1 mM sodium orthovanadate, and 2% Sigma protease inhibitor cocktail) with periodic vortexing to resuspend tissue fragments. Samples were centrifuged at 10,000 g for 10 min, and the supernatant was collected and filtered through 0.45-m Ultrafree-MC centrifugal filter unit (Millipore) to remove any residual particulate matter. Protein concentration in lung lysates was determined by the Bradford assay (Bio-Rad, Hercules, CA) and samples were aliquoted and stored at Ϫ80°C until use.
Total hyaluronidase activity by Morgan Elson assay. Total hyaluronidase activity of rat lung lysates was determined by a fluorimetric Morgan Elson assay, as described by Takahashi and colleagues (39) . Lung lysate samples (20 g, diluted to 10 l with 0.15 M NaCl) were added to 120 l of HA substrate solution and incubated at 37°C for 40 min. HA substrate solution was prepared by dissolving 1.5 mg/ml HA (from rooster comb, Sigma) in formate buffer (0.1 M formic acid, 0.1 M NaCl, and 1.5 mM saccharic acid 1,4-lactone, pH 3.5) overnight at 4°C. Standards to determine the linear range of the assay were prepared by adding known concentrations of N-acetyl-D-glucaosamine (Sigma) to formate buffer. A zero for the assay was prepared by adding HA substrate solution to a lysate sample immediately before boiling.
Total hyaluronidase activity by TBE PAGE. HA oligosaccharides, generated by incubation of substrate HA with lung lysate samples, were analyzed by Tris-borate-EDTA (TBE) polyacrylamide gel electrophoresis (PAGE), as described by Ikegami-Kawai and Takahashi (19) . Lung lysate samples, containing 100 g of protein, diluted to 10 l with 0.15 M NaCl, were incubated with 120-l HA substrate solution (as described for Morgan Elson assay) for 1.5 h at 37°C.
Hyaluronidase zymography. Hyaluronidase zymography was performed as described by Ikegami-Kawai et al. (18) . Rooster comb HA (Sigma) was dissolved at a concentration of 1 mg/ml in distilled, deionized water overnight at 4°C and incorporated into 7% SDS-PAGE gels to give a final HA concentration of 170 g/ml. For each sample, 12.5 g of protein were diluted to 10 l with 0.15 M NaCl, mixed with an equal volume of 2ϫ Laemmli's SDS loading buffer (without ␤-mercaptoethanol), and incubated at 37°C for 1 h to denature the proteins before loading the samples into the gel.
Hyaluronidase reverse zymography. Reverse zymography for hyaluronidase inhibitors was performed as described by Mio and colleagues (29) . For each sample, 100 g of protein were diluted to 15 l with 0.15 M NaCl, mixed with an equal volume of 2ϫ Laemmli's SDS loading buffer (without ␤-mercaptoethanol), and loaded into the gel.
Data analysis. All data are presented as means Ϯ SE. Comparisons between MCT-challenged and normal control groups were performed separately for each time point by Student's t-test.
RESULTS

Quantification of MCT-induced PH.
Intraperitoneal injection of MCT induced PH in Fisher 344 rats, as indicated by elevated RVSP (Fig. 1A) and RV hypertrophy (Fig. 1B) . Increased RVSP in response to MCT challenge was not detectable at 10 days post-MCT, but was observed in the form of a moderate elevation at 24 days after MCT injection and advanced PH at 28 days post-MCT. Analysis of RV hypertrophy demonstrated a similar trend, with no measurable hypertrophy at 10 days, moderate hypertrophy at 24 days, and more severe hypertrophy at 28 days.
Distribution of lung HA in MCT-induced PH. Probing fixed lung sections from both normal and MCT-treated rats for HA revealed progressive changes in the localization of lung HA that accompanied the progression from moderate to advanced PH (Fig. 1, C-F) . The healthy lungs of normal F344 rats (Fig.  1C) showed a consistent amount of HA associated with the microvasculature and surrounding larger vessels. At 10 days post-MCT (Fig. 1D) , a marked decrease in the amount of microvasculature-associated HA was visible, accompanied by a slight elevation in the level of HA associated with precapillary arterioles. By 24 days post-MCT (Fig. 1E) , accumulation of HA was localized to the muscularized precapillary arterioles, but was absent from large areas of the microvasculature. At 28 days, a significant accumulation of HA was not only observed surrounding muscularized arterioles, but was also found in association with large cellular infiltrates that were present throughout the lungs (Fig. 1F) .
Localization of pulmonary gylycosaminoglycans within the vascular wall was also assessed by transmission electron microscopy (Fig. 2) . Rat lungs were fixed in the presence of ruthenium red, a polycationic dye that binds to GAGs, forming strings of dark precipitates in electron microscopy images. At 24 days postinjection, analysis of pulmonary arterioles in MCT-challenged rats (Figs. 2, A and B) revealed endothelial desquamation and marked perivascular matrix accumulation. Matrix-associated GAG accumulation was highlighted by ruthenium red precipitates lining collagen fibrils. Arterioles from normal control animals (Fig. 2C ) displayed intact endothelium, with no matrix accumulation and limited dye precipitates.
Quantification and molecular mass distribution of lungderived HA. Quantification of total lung HA by ELISA revealed a decrease in total lung HA in MCT-challenged animals at 10 days post-MCT compared with saline-treated controls (Fig. 3) . While a trend toward decreased total lung HA was also observed at 24 days post-MCT, assessment of 28-day samples revealed a significant increase in total lung HA in MCT-challenged animals compared with saline-treated controls, associated with the progression from moderate to advanced PH.
Agarose gel electrophoresis was used to determine the molecular mass distribution of lung-derived GAGs isolated at 10, 24, and 28 days post-MCT. Molecular mass analysis demonstrated a relative decrease in the highest molecular mass portion of HMM HA (ϳ4 ϫ 10 6 to 1.5 ϫ 10 6 Da, blue stain) in the lungs of MCT-challenged rats at 10 days, before the onset of elevated pressures and vascular muscularization (Fig. 4A) . By 24 days, this relative decrease in HMM HA (Ͼ1.5 ϫ 10 6 Da) was more pronounced. In contrast, the molecular mass profile for lungderived HA at 28 days post-MCT demonstrated a relative increase in HMM HA, corresponding to the increase in total lung HA demonstrated by ELISA. Notably, HMM HA in the range of 5 ϫ 10 5 to 1.5 ϫ 10 6 Da did not appear to be altered in response to MCT challenge.
Interference from sulfated GAGs (purple) prevented the determination of LMM HA (5 ϫ 10 5 to 2.5 ϫ 10 4 Da) content in the lungs by this technique. To assess the relative quantities of LMM HA in lung isolates, GAGs corresponding to this molecular mass range were recovered from agarose gels by electroelution, and the relative HA content of this fraction was quantified by ELISA (Fig. 4B) . Quantification revealed a relative increase in LMM HA in MCT-challenged rats at 10 and 24 days, but not at 28 days postinjection. (HAS1, HAS2, and HAS3) by real-time RT-PCR demonstrated no significant changes in the expression of HAS1 at 10 and 28 days post-MCT, but did show a slight yet significant increase at 24 days post-MCT (1.7-fold, P ϭ 0.004; Fig. 5A ). For HAS2, a 3.5-fold increase (P ϭ 0.001) in relative expression was observed by 24 days post-MCT, which increased to 6.1-fold (P ϭ 0.003) by 28 days post-MCT. In contrast, 1.4-fold (P ϭ 0.04), 4.9-fold (P Ͻ 0.0001), and 5.2-fold (P ϭ 0.0001) decreases in relative expression of HAS3 were observed at 10, 24, and 28 days post-MCT, respectively.
Analysis of HAS and hyaluronidase expression by real-time RT-PCR. Relative expression analysis of the HAS genes
Analysis of hyaluronidase (HYAL1 and HYAL2) gene expression demonstrated no significant changes in HYAL1 or HYAL2 expression at 10 days post-MCT (Fig. 5B) . At 24 days, real-time RT-PCR analysis revealed a 1.7-fold decrease in HYAL1 (P ϭ 0.0006) and a 1.7-fold decrease in HYAL2 expression (P ϭ 0.0005) in MCT-challenged animals. Similar decreases (1.8-fold, P ϭ 0.01, for HYAL1 and 2.1-fold, P ϭ 0.007 for HYAL2) were also observed at 28 days postinjection.
Analysis of total pulmonary hyaluronidase activity. Total hyaluronidase activity in lung lysates from MCT-treated and control rats was determined by the fluorometric Morgan-Elson method (39) . At 10 days post-MCT, the total hyaluronidase activity in the lungs of MCT-challenged rats remained unchanged from that of normal controls (Fig. 6A) . In contrast to the results from the real-time RT-PCR analysis of hyaluronidase gene expression, the development of moderate PH at 24 days post-MCT and advanced PH at 28 days was accompanied by a significant increase in total hyaluronidase activity at both time points. TBE-PAGE analysis of HA fragments, generated following incubation of HMM HA substrate with lung lysates, was used to confirm the results of the Morgan Elson assay and to determine the relative activities of Hyal1 and Hyal2. While Hyal1 cleaves HA into oligosaccharide fragments, Hyal2 degrades HA molecules into larger segments of ϳ20 kDa (14) . As an indication of enhanced Hyal1 activity, silver staining of TBE-PAGE gels demonstrated a ladder of HA oligosaccharides varying by single tetrasaccharide units for samples from MCT-challenged rats at 24 and 28 days, but not 10 days post-MCT (Fig. 6B) . Densitometric analysis of HA fragments at the 20-kDa molecular mass range revealed no significant increase associated with MCT-challenged animals at any time point (data not shown), suggesting that the observed increase in total hyaluronidase activity was not due to increased activity of Hyal2.
Hyaluronidase zymography and reverse zymography. To confirm an increase in Hyal1 activity in response to MCT challenge, we performed hyaluronidase zymography on lung lysates. Zymography revealed the presence of a single hyaluronidase with a primary band at ϳ73 kDa and a trace band at ϳ63 kDa (Fig. 7A) , which was previously identified as differentially glycosylated forms of Hyal1 (14, 18) . In contrast, with results from the Morgan Elson assay, quantification of hyaluronidase zymograpy by densitometry revealed a significant increase in Hyal1 in MCT-challenged animals at 10 days post-MCT, before the onset of elevated RVSP (Fig. 7B) . Trends toward increased Hyal1 activity were also observed at both 24 and 28 days post-MCT. Because of the apparent discrepancy between the results from the Morgan Elson assay and the hyaluronidase zymography, analysis of hyaluronidase inhibitors by reverse zymography was performed on lung lysates. Reverse zymography revealed a single hyaluronidase inhibitor at a molecular mass of ϳ120 kDa (Fig. 7C) . Quantification of hyaluronidase inhibitor levels by densitometry demonstrated a significant increase in MCT-challenged animals at all three time points, with the highest increase appearing at 10 days post-MCT (Fig. 7D) .
DISCUSSION
In this study, we demonstrated changes in the distribution, synthesis, and enzymatic degradation of pulmonary HA associated with the onset and progression of MCT-induced PH. We now show that the early stages of MCT-induced PH are not associated with increased HA within the lung, but instead are linked to a loss of total lung HA at 10 days post-MCT and a trend toward decreased lung HA at 24 days. Increased total lung HA was only observed at 28 days post-MCT, in association with advanced disease, which is consistent with previous reports demonstrating an accumulation of HA in the lungs of patients with established IPAH (33) . This observation, which was likely due to the large increase in HA associated with diffuse cell infiltrates, suggests that the accumulation of HA in the lungs, as reported in clinical PAH, is a marker of more advanced disease and may be less relevant at earlier stages of disease progression.
HA degradation fragments are highly inflammatory, and their generation in early-stage disease could act as the driving force behind the chronic inflammation and vascular remodeling observed in both the MCT model and clinical cases of IPAH. In IPAH, this inflammation is characterized by the accumulation of mononuclear inflammatory cells in areas of pulmonary vascular remodeling (16, 46) , as well as increased levels of proinflammatory cytokines, chemokines, and growth factors (11, 12, 15) . In the MCT model, acute inflammation has been reported in the pulmonary microvasculature as early as 8 -16 h after MCT injection, likely in response to the initial, MCTinduced endothelial injury and resultant increase in vascular permeability (51) . However, over the first few days post-MCT, this acute inflammatory response gives way to a period of chronic inflammation, observed as early as 7-14 days post-MCT, which is similar to that observed in clinical cases of IPAH (22, 34, 49, 51) . Our assessment of HA synthesis and metabolism in the MCT model, from 10 to 28 days post-MCT, was limited to this later period of chronic inflammation.
Fig. 4. Molecular mass (MM) analysis of lung-derived GAGs.
A: stains-all treatment of a 0.5% agarose gel containing GAG samples isolated from normal control or MCT-treated Fisher 344 rats at 10, 24, and 28 days post-MCT. HA, which is not sulfated, appears blue after treatment with stains-all and can be distinguished from other sulfated GAGs, which appear purple. In MCT-treated rats, high MM (HMM) HA (Ͼ500 kDa) is decreased at 10 days post-MCT and completely absent at 24 days. By 28 days, MCT-challenged rats show increased levels of HMM HA compared with time-matched controls. B: relative quantification of low MM (LMM) HA (Ͻ500 kDa) by ELISA. LMM HA samples were recovered from agarose gels by electroelution. Representative data were generated using pooled GAG isolates from 5 animals. Values are means Ϯ SE. *P Յ 0.05. In agreement with the alterations in the absolute quantity of lung HA, we observed changes in HA distribution at all time points post-MCT, including at 10 days, before the development of elevated RVSP and RV hypertrophy. Specifically, there was a loss of HA in the distal microvasculature and an accumulation around the pulmonary arterioles (25-50 m in diameter), which exhibit muscularization at later time points. This finding was supported by transmission electron microscopy analysis of ruthenium red-stained rat lungs at 24 days postinjection, which demonstrated a marked accumulation of GAGs in the subendothelial layer of arterioles from MCT-challenged rats compared with normal controls. This accumulation of HA around arterioles suggests a potential role for HA in the promotion of SMC proliferation and muscularization at these sites and is consistent with similar findings in models of atherosclerosis (7) and balloon catheter-induced aortic injury (4).
Although the enhanced synthesis of anti-inflammatory HMM HA (ϳ4,000 kDa) has been reported previously for PA SMCs derived from IPAH patients (2), our analysis of the molecular mass distribution for rat lung-derived GAGs only revealed an increase in HMM HA in association with advanced PH at 28 days post-MCT. At earlier time points, we observed a relative decrease in the highest molecular mass portion of lung-derived HMM HA (Ͼ1.5 ϫ 10 6 Da) at 10 days post-MCT, that became more pronounced at 24 days. While interference from other, sulfated GAGs prevented the assessment of LMM HA by staining of the agarose gel, electroelution of LMM GAG isolates from the agarose gels and subsequent quantification by ELISA revealed that the loss of HMM HA at 10 and 24 days post-MCT is accompanied by a concordant increase in bioactive LMM HA fragments (Ͻ500 kDa).
When assessing the balance of HA in the lung, it is also important to consider the impact that an elevation in pulmonary arterial pressure may have on HA turnover. The HA content of the lung is not only governed by local synthesis and degradation, but is also influenced by the throughput of fluid across the pulmonary endothelial barrier, through the interstitium, and into lung lymph. Previous reports have shown that this washout of interstitial HA into the lymph is enhanced in the presence of elevated intravascular pressure (36, 45) . This enhanced clearance of HA may help to explain our failure to observe elevated LMM HA content in MCT-challenged rats in association with severe PH at 28 days, despite the persistent elevation of total lung hyaluronidase activity at this time point.
In models of ventilator-induced lung injury, the accumulation of LMM HA in the lung was linked to increased expression of HAS3 (27) , which synthesizes HA with an average molecular mass of ϳ250 kDa (20) . In contrast, we found that, not only was HAS3 expression decreased in MCT-treated animals at all three time points, but HAS2 expression was significantly increased at both 24 and 28 days post-MCT. The HAS2 enzyme has been reported to produce HMM isoforms of HA, with a mean molecular mass of ϳ4,000 kDa (20) . These data suggest that the loss of HMM HA in association with the early stages of MCT-induced PH was not due to the preferential synthesis of LMM forms of HA, but could instead be the result of enhanced degradation of newly synthesized HMM HA.
In mammalian stromal tissue, HA degradation is primarily regulated by two members of the hyaluronidase family, Hyal2, which is localized to the plasma membrane and cleaves large HA molecules into intermediate segments of ϳ20 kDa, and Hyal1, which is localized to lysosomes, where it cleaves these intermediate HA fragments into oligosaccharides of HA (38) . Both enzymatic degradation products have been shown to induce inflammatory effects. Hyal2 degradation fragments have been reported to induce the secretion of inflammatory cytokines (31) , and HA oligosaccharides, such as those observed in the TBE-PAGE gels, have been shown to stimulate increased cell adhesion molecule expression on endothelial cells (41) and induce dendritic cell activation through toll-like receptor signaling (43) . HA oligosaccharides have also been shown to induce synthesis of HMM HA through enhanced HAS2 expression, potentially as a compensatory mechanism to counteract the proinflammatory effects of LMM HA generated after tissue injury. This stress-responsive mechanism could explain our observation of increased HAS2 gene expression at While gene expression analysis of hyaluronidases demonstrated decreased expression of HYAL1 and HYAL2 mRNA in MCT-challenged animals at both 24 and 28 days, analysis of total lung hyaluronidase activity by the Morgan Elson assay and TBE-PAGE demonstrated increased Hyal1 activity at these time points. The decrease in HYAL2 gene expression at later stages of disease is in agreement with previous studies that demonstrated relative decreases in HYAL2 expression in both lung tissue and pulmonary artery smooth muscle cells isolated from IPAH patients (2, 33) . However, our observed disconnect between gene expression and enzyme activity is also in agreement with the findings of one of these studies (2) that demonstrated a decrease in HYAL2 mRNA expression without changes in protein expression. When taken together, our enzymatic activity and gene expression data indicate that HYAL activity in the lung may be posttranscriptionally or posttranslationally regulated and suggest the potential existence of a regulatory feedback mechanism of hyaluronidase activity on HYAL gene expression.
Analysis of hyaluronidase zymography demonstrated a significant elevation in Hyal1 at 10 days post-MCT. While this result differs from the data obtained from the Morgan Elson and TBE-PAGE assays, increased hyaluronidase activity at this early time point is consistent with the decreased total lung HA and altered HA distribution observed at 10 days post-MCT. The discrepancy between the Morgan Elson and zymography assays could be explained by the presence of increased hyaluronidase inhibitor activity in lung lysates from MCT-treated rats. While such an inhibitor could decrease total hyaluronidase activity in solution, electrophoretic techniques, such as zymography, separate inhibitors from their enzymatic targets, giving a measure of total active enzyme. Taken together, these results suggest that the increased hyaluronidase activity detected in the lung following MCT challenge may be dependent on the balance between increased Hyal1 and compensatory inhibitor activity. As with the relationship between matrix metalloproteinases and their tissue inhibitors, the translation of this in vitro result to the in vivo relationship between hyaluronidases and their inhibitors is highly dependent on the spatial localization of the two proteins within the lung tissue (48) .
The identification of compensatory hyaluronidase inhibitor activity in the lungs of MCT-challenged rats also supports the potential clinical application of hyaluronidase inhibition as a treatment for early stage PAH. While little is known about the structure, function, activity, or specificity of endogenous hyaluronidase inhibitors, some studies have reported the successful inhibition of hyaluronidase activity by small molecules (3, 32) . Vcpal (L-ascorbic acid 6-hexadecanoate), a modified from of L-ascorbic acid, has been shown to be a potent inhibitor of hyaluronidases in in vitro assays of isolated enzymes (3) and may be a viable option for the treatment of early-stage PAH. However, since patients often do not present until later in disease progression (17) , the potential of hyaluronidase inhibition as a therapeutic strategy for PAH may be limited.
In summary, our data from the rat model of MCT-induced PH supports the results from previous studies with human IPAH patients, which demonstrated an accumulation of HA in association with established disease (2, 33) . However, our use of the MCT rat model also allowed for a more detailed examination of the early stages of disease development, which are associated with the increased enzymatic degradation of pulmonary HA. The findings presented in this study suggest that the regulation of HA in PAH may be divisible into two distinct stages, with the enzymatic degradation of HA and the generation of proinflammatory HA degradation fragments predominating in early disease development and an increase in the synthesis of anti-inflammatory HMM HA characterizing more established disease. The observation of enhanced HA degradation early in the progression of MCT-induced PH sheds new light on the potential role of the extracellular matrix in the pathogenesis of PAH. The early generation of HA degradation fragments may provide the inflammatory and proliferative stimulus to drive pathological vascular remodeling and may also present a viable target for clinical therapeutic intervention.
